Literature DB >> 21728066

Voiding dysfunction in the female patient: is the "syndrome" paradigm valid?

Hari Siva G R Tunuguntla1, Renuka Tunuguntla, Joseph Barone, Prashanth Kanagarajah, Angelo E Gousse.   

Abstract

Voiding dysfunction in the female patient significantly affects the patient's quality of life. The condition is poorly understood, has varied etiology and clinical presentation, and lacks standard definitions with no consensus on diagnostic criteria. It consists of a constellation of symptoms involving both phases of the micturition cycle. Appropriate diagnosis and treatment of female lower urinary tract symptoms (LUTS) is of paramount importance. However, the differentiation of female LUTS into various syndromes is currently controversial. This article comprehensively reviews the commonly encountered female non-neurogenic LUTS (overactive bladder, interstitial cystitis, and painful bladder syndrome); discusses the contemporary management of these syndromes; and emphasizes a syndromic approach to the condition. © Springer Science+Business Media, LLC 2011

Entities:  

Mesh:

Year:  2011        PMID: 21728066     DOI: 10.1007/s11934-011-0207-z

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  18 in total

1.  An assessment of the use of intravesical potassium in the diagnosis of interstitial cystitis.

Authors:  G K Chambers; H N Fenster; S Cripps; M Jens; D Taylor
Journal:  J Urol       Date:  1999-09       Impact factor: 7.450

2.  Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis.

Authors:  M A Denson; T L Griebling; M B Cohen; K J Kreder
Journal:  J Urol       Date:  2000-12       Impact factor: 7.450

3.  The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

4.  The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

Authors:  Christopher Chapple; Dirk De Ridder
Journal:  BJU Int       Date:  2009-08-13       Impact factor: 5.588

5.  On syndromes, symptoms, and root cause.

Authors:  Roger Dmochowski
Journal:  Eur Urol       Date:  2008-03-18       Impact factor: 20.096

6.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

7.  Intravesical lignocaine in the diagnosis of bladder pain syndrome.

Authors:  Rajesh Taneja
Journal:  Int Urogynecol J       Date:  2010-03       Impact factor: 2.894

Review 8.  Management of overactive bladder syndrome.

Authors:  Sushma Srikrishna; Dudley Robinson; Linda Cardozo; Maria Vella
Journal:  Postgrad Med J       Date:  2007-07       Impact factor: 2.401

9.  Overlap of different urological symptom complexes in a racially and ethnically diverse, community-based population of men and women.

Authors:  Michael J Barry; Carol L Link; Mary F McNaughton-Collins; John B McKinlay
Journal:  BJU Int       Date:  2007-09-13       Impact factor: 5.588

10.  The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study.

Authors:  P M Hanno; J R Landis; Y Matthews-Cook; J Kusek; L Nyberg
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.